Resmed (RSMDF) Accounts Payables (2010 - 2026)

Resmed has reported Accounts Payables for 17 years, with the latest figure at $273.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 22.8% year-over-year to $273.3 million; the trailing twelve-month figure through Mar 2026 stood at $273.3 million (up 22.8% YoY), and the FY2025 full-year result was $278.2 million, up 17.01% from the prior year.
• Accounts Payables for Q1 2026 stood at $273.3 million, up from $250.4 million in the prior quarter.
• The five-year high for Accounts Payables was $278.2 million in Q2 2025, with the low at $149.8 million in Q1 2022.
• Historically, Accounts Payables has averaged $209.1 million across 5 years, with a median of $202.4 million in 2023.
• Annual changes were most pronounced in 2023 — Accounts Payables declined 5.33% — and 2024, when it soared 57.69%.
• Resmed's Accounts Payables stood at $196.0 million in 2022, then gained by 3.26% to $202.4 million in 2023, then climbed by 8.85% to $220.3 million in 2024, then gained by 13.66% to $250.4 million in 2025, then advanced by 9.14% to $273.3 million in 2026.
• The last three Accounts Payables figures came in at $273.3 million (Q1 2026), $250.4 million (Q4 2025), and $266.8 million (Q3 2025), per Business Quant data.